Updates on Amgen (NASDAQ: AMGN) ratings and price targets.
Bank of America (NYSE: BAC) raised their price target on Amgen (AMGN) to $65.00.
Citigroup (NYSE: C) raised their price target on Amgen to $73.00. They have a “Buy” rating on the company.
Piper Jaffray (NYSE: PJC) reiterated a “Neutral” rating on Amgen. They have a price target of $65.00 on the company.
TheStreet upgraded Amgen to a “Buy” rating.
UBS AG (NYSE: UBS) raised their price target on Amgen (AMGN) to $59.00. They have a “Neutral” rating on the company.
Barclays Capital (BCS) initiated coverage on Amgen. They placed an “Equal Weight” rating and a price target of $65.00 on the company.
Showing posts with label Amgen. Show all posts
Showing posts with label Amgen. Show all posts
Friday, December 30, 2011
Amgen (AMGN) (ALXN) (FRNK) (BIDU) (CEDU) (KEM) Ratings, Price Targets
Amgen, Inc. (NASDAQ: AMGN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Franklin Financial (NASDAQ: FRNK), Baidu.com, Inc. (NASDAQ: BIDU), ChinaEdu (NASDAQ: CEDU) and KEMET Co. (NYSE: KEM) ratings and price targets.
Amgen, Inc. (AMGN) had its price target raised by Bank of America (NYSE:BAC) to $65.00.
Alexion Pharmaceuticals, Inc. (ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Sandler O'Neill initiated coverage on Franklin Financial (FRNK). They placed a “Hold” rating on the company.
Baidu.com, Inc. (BIDU) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
ChinaEdu (CEDU) was downgraded by Zacks Investment Research from a “Neutral” rating to an “Underperform” rating.
KEMET Co. (KEM) was upgraded by Zacks Investment Research from an “Underperform” rating to a “Neutral” rating.
Amgen, Inc. (AMGN) had its price target raised by Bank of America (NYSE:BAC) to $65.00.
Alexion Pharmaceuticals, Inc. (ALXN) had its “Outperform” rating reiterated by Leerink Swann.
Sandler O'Neill initiated coverage on Franklin Financial (FRNK). They placed a “Hold” rating on the company.
Baidu.com, Inc. (BIDU) was downgraded by Zacks Investment Research from an “Outperform” rating to a “Neutral” rating.
ChinaEdu (CEDU) was downgraded by Zacks Investment Research from a “Neutral” rating to an “Underperform” rating.
KEMET Co. (KEM) was upgraded by Zacks Investment Research from an “Underperform” rating to a “Neutral” rating.
Tuesday, December 20, 2011
Amgen (AMGN) (SNDA) (ALE) (CLD) (COH) (EOG) Ratings, Price Targets
Amgen, Inc. (NASDAQ: AMGN), Shanda Interactive Entertainment (NASDAQ: SNDA), ALLETE, Inc. (NYSE: ALE), Cloud Peak Energy (NYSE: CLD), Coach (NYSE: COH) and EOG Resources (NYSE: EOG) ratings and price targets.
Piper Jaffray (NYSE:PJC) reiterated its "Neutral" rating on Amgen, Inc. (AMGN). They have a price target of $65.00 on the company.
Shanda Interactive Entertainment (SNDA) was upgraded by Zacks Investment Research from an “Underperform” rating to a “Neutral” rating.
DA Davidson reiterated its "Neutral" rating on ALLETE, Inc. (ALE). They have a price target of $41.00 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Cloud Peak Energy (CLD). They placed a “Neutral” rating on the company.
Collins Stewart initiated coverage on Coach (COH). They placed a “Neutral” rating and a price target of $67.00 on the company.
EOG Resources (EOG) was downgraded by Scotia Capital from an “Outperform” rating to a “Sector Perform” rating.
Piper Jaffray (NYSE:PJC) reiterated its "Neutral" rating on Amgen, Inc. (AMGN). They have a price target of $65.00 on the company.
Shanda Interactive Entertainment (SNDA) was upgraded by Zacks Investment Research from an “Underperform” rating to a “Neutral” rating.
DA Davidson reiterated its "Neutral" rating on ALLETE, Inc. (ALE). They have a price target of $41.00 on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Cloud Peak Energy (CLD). They placed a “Neutral” rating on the company.
Collins Stewart initiated coverage on Coach (COH). They placed a “Neutral” rating and a price target of $67.00 on the company.
EOG Resources (EOG) was downgraded by Scotia Capital from an “Outperform” rating to a “Sector Perform” rating.
Friday, December 16, 2011
Amgen (AMGN) Upgraded by Goldman Sachs (GS)
Amgen (NASDAQ: AMGN) was upgraded by Goldman Sachs (NYSE:GS) on Friday.
They boosted the company from a "Sell" rating to a "Neutral" rating.
Earlier in the week UBS (NYSE: UBS) also boosted its price target on the company to $59.00. They have a "Neutral" rating on the company.
Amgen was trading at $60.78, up $2.16, or 3.68 percent, as of 12:03 PM EST.
They boosted the company from a "Sell" rating to a "Neutral" rating.
Earlier in the week UBS (NYSE: UBS) also boosted its price target on the company to $59.00. They have a "Neutral" rating on the company.
Amgen was trading at $60.78, up $2.16, or 3.68 percent, as of 12:03 PM EST.
Tuesday, November 15, 2011
Anadys (ANDS) (SDT) (AMGN) (SPF) (TEF) (ALIM) Downgraded
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS), SandRidge Mississippian Trust I (NYSE: SDT), Amgen, Inc. (NASDAQ: AMGN), Standard Pacific Corp. (NYSE: SPF), Telefonica SA (NYSE: TEF) and Alimera Sciences Inc. (NASDAQ: ALIM) were downgraded by analysts.
Anadys Pharmaceuticals, Inc. (ANDS) was downgraded by William Blair from an “Outperform” rating to a “Market Perform” rating.
SandRidge Mississippian Trust I (SDT) was downgraded by Robert W. Baird from an “Outperform” rating to a “Neutral” rating. They have a price target of $24.00 on the stock, down from $30.00.
Amgen, Inc. (AMGN) was downgraded by Leerink from an “Outperform” rating to a “Market Perform” rating.
Standard Pacific Corp. (SPF) was downgraded by Compass Point to a “Neutral” rating. They have a price target of $3.50 on the company.
Telefonica SA (TEF) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.
Alimera Sciences Inc. (ALIM) was downgraded by Citigroup (NYSE:C) from a “Buy” rating to a “Neutral” rating.
Anadys Pharmaceuticals, Inc. (ANDS) was downgraded by William Blair from an “Outperform” rating to a “Market Perform” rating.
SandRidge Mississippian Trust I (SDT) was downgraded by Robert W. Baird from an “Outperform” rating to a “Neutral” rating. They have a price target of $24.00 on the stock, down from $30.00.
Amgen, Inc. (AMGN) was downgraded by Leerink from an “Outperform” rating to a “Market Perform” rating.
Standard Pacific Corp. (SPF) was downgraded by Compass Point to a “Neutral” rating. They have a price target of $3.50 on the company.
Telefonica SA (TEF) was downgraded by JPMorgan Chase & Co. (NYSE:JPM) from an “Overweight” rating to a “Neutral” rating.
Alimera Sciences Inc. (ALIM) was downgraded by Citigroup (NYSE:C) from a “Buy” rating to a “Neutral” rating.
Tuesday, August 2, 2011
Apple (AAPL) (AMGN) (CVS) (PNC) (SAPE) (TRN) Price Target Changed
Apple, Inc. (NASDAQ: AAPL), Amgen, Inc. (NASDAQ: AMGN), CVS Caremark (NYSE: CVS), PNC Financial Services (NYSE: PNC), Sapient Co. (NASDAQ: SAPE) and Trinity Industries, Inc. (NYSE: TRN) price target adjusted by analysts.
Apple, Inc. (AAPL) had its price target raised by Canaccord Genuity from $510.00 to $515.00. They have a “Buy” rating on the company.
Amgen, Inc. (AMGN) had its price target raised by UBS AG (NYSE:UBS) to $58.00. They have a “Neutral” rating on the company.
CVS Caremark (CVS) had its price target raised by JPMorgan Chase & Co. (NYSE:JPM) to $50.00.
PNC Financial Services (PNC) had its price target lowered by Stifel Nicolaus from $85.00 to $82.00. They have a “Buy” rating on the company.
Sapient Co. (SAPE) had its price target raised by Stifel Nicolaus from $17.00 to $19.00. They have a “Buy” rating on the company.
Trinity Industries, Inc. (TRN) had its price target cut by Longbow Research from $44.00 to $41.00. They have a “Buy” rating on the company.
Apple, Inc. (AAPL) had its price target raised by Canaccord Genuity from $510.00 to $515.00. They have a “Buy” rating on the company.
Amgen, Inc. (AMGN) had its price target raised by UBS AG (NYSE:UBS) to $58.00. They have a “Neutral” rating on the company.
CVS Caremark (CVS) had its price target raised by JPMorgan Chase & Co. (NYSE:JPM) to $50.00.
PNC Financial Services (PNC) had its price target lowered by Stifel Nicolaus from $85.00 to $82.00. They have a “Buy” rating on the company.
Sapient Co. (SAPE) had its price target raised by Stifel Nicolaus from $17.00 to $19.00. They have a “Buy” rating on the company.
Trinity Industries, Inc. (TRN) had its price target cut by Longbow Research from $44.00 to $41.00. They have a “Buy” rating on the company.
Amgen (AMGN) (HP) (SWN) (WY) (NWL) (OI) EPS Estimates Changed
Amgen, Inc. (NASDAQ: AMGN), Helmerich & Payne (NYSE: HP), Southwestern Energy (NYSE: SWN), Weyerhaeuser (NYSE: WY), Newell Rubbermaid (NYSE: NWL) and Owens-Illinois (NYSE: OI) EPS estimated adjusted.
Oppenheimer lowered its EPS estimates on Amgen, Inc. (AMGN). They have an “Outperform” rating and a price target of $66.00 on the company.
Goldman Sachs (NYSE:GS) boosted its EPS estimates on Helmerich & Payne (HP). They have a “Neutral” rating and a price target of $80.00 on the company.
Morgan Stanley (NYSE:MS) raised its EPS estimates on Southwestern Energy (SWN). They have a “Neutral” rating and a price target of $51.00 on the company.
UBS AG (NYSE:UBS) cuts its EPS estimates Weyerhaeuser (WY). They have a “Sell” rating and a price target of $18.00 on the company.
Morgan Stanley cut its EPS estimates on Newell Rubbermaid (NWL). They have an “Overweight” rating and a price target of $20.00 on the company.
Goldman Sachs cut its EPS estimates on Owens-Illinois (OI). They have a “Neutral” rating and a price target of $28.00 on the company.
Oppenheimer lowered its EPS estimates on Amgen, Inc. (AMGN). They have an “Outperform” rating and a price target of $66.00 on the company.
Goldman Sachs (NYSE:GS) boosted its EPS estimates on Helmerich & Payne (HP). They have a “Neutral” rating and a price target of $80.00 on the company.
Morgan Stanley (NYSE:MS) raised its EPS estimates on Southwestern Energy (SWN). They have a “Neutral” rating and a price target of $51.00 on the company.
UBS AG (NYSE:UBS) cuts its EPS estimates Weyerhaeuser (WY). They have a “Sell” rating and a price target of $18.00 on the company.
Morgan Stanley cut its EPS estimates on Newell Rubbermaid (NWL). They have an “Overweight” rating and a price target of $20.00 on the company.
Goldman Sachs cut its EPS estimates on Owens-Illinois (OI). They have a “Neutral” rating and a price target of $28.00 on the company.
Tuesday, July 19, 2011
Amgen (AMGN) (ASH), (AWK) (CHKP) (DNDN) (EPD) Ratings Reiterated
Amgen, Inc. (NASDAQ: AMGN), Ashland Inc. (NYSE: ASH), American Water Works Co Inc (NYSE: AWK), Check Point Software ((NASDAQ: CHKP), Dendreon Co. (NASDAQ: DNDN), Enterprise Products Partners (NYSE: EPD) ratings reiterated by analysts.
Amgen, Inc. (AMGN) rating reiterated an “overweight” by at Piper Jaffray.
Ashland Inc. (ASH) rating reiterated a “neutral” by JPMorgan Chase & Co. (NYSE:JPM).
American Water Works Co Inc (AWK) rating reiterated a “neutral” by Ladenburg Thalmann.
Check Point Software (CHKP) rating reiterated an “outperform” by Oppenheimer.
Dendreon (DNDN) rating reiterated a “hold” by Citigroup (NYSE:C). They have a price target of $36.00 on the company.
Enterprise Products Partners (EPD) rating reiterated a “buy” by Wunderlich. They have a price target of $48.00 on the company.
Amgen, Inc. (AMGN) rating reiterated an “overweight” by at Piper Jaffray.
Ashland Inc. (ASH) rating reiterated a “neutral” by JPMorgan Chase & Co. (NYSE:JPM).
American Water Works Co Inc (AWK) rating reiterated a “neutral” by Ladenburg Thalmann.
Check Point Software (CHKP) rating reiterated an “outperform” by Oppenheimer.
Dendreon (DNDN) rating reiterated a “hold” by Citigroup (NYSE:C). They have a price target of $36.00 on the company.
Enterprise Products Partners (EPD) rating reiterated a “buy” by Wunderlich. They have a price target of $48.00 on the company.
Thursday, July 14, 2011
Apple (AAPL) (AMGN) (GILD) (INFY) (NWSA) EPS Estimates Changed by Analysts
Apple, Inc (NASDAQ: AAPL), Amgen, Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Infosys Technologies Ltd (NASDAQ: INFY) and News Corp. (NASDAQ: NWSA) had EPS estimates adjusted by analysts.
UBS AG (NYSE:UBS) boosted Apple, Inc (AAPL)‘s EPS estimate. They have a “Buy” rating and a price target of $510.00 on the company.
UBS AG raised Amgen, Inc. (AMGN) ‘s EPS estimate. They have a “neutral” rating and a price target of $58.00 on the company.
UBS AG cut its EPS estimate on Gilead Sciences, Inc. (GILD). They have a “Buy” rating and a price target of $47.00 on the company.
Oppenheimer increased its EPS estimate on Infosys Technologies Ltd (INFY). They have a “market perform” rating on the company.
Barclays Capital raised its EPS estimate on News Corp. (NWSA). They have an “Equal Weight” rating and a price target of $20.00 on the company. They had had a “Buy” rating on the company before the change.
News Corp. (NWSA) closed Wednesday at $15.93, gaining $0.58, or 3.78 percent. Infosys Technologies closed at $61.26, falling $0.18, or 0.29 percent. Gilead Sciences closed at $41.61, rising $0.06, or 0.14 percent. Amgen closed at $56.61, dropping $0.29, or 0.51 percent. Apple closed at $358.02, jumping $4.27, or 1.21 percent.
UBS AG (NYSE:UBS) boosted Apple, Inc (AAPL)‘s EPS estimate. They have a “Buy” rating and a price target of $510.00 on the company.
UBS AG raised Amgen, Inc. (AMGN) ‘s EPS estimate. They have a “neutral” rating and a price target of $58.00 on the company.
UBS AG cut its EPS estimate on Gilead Sciences, Inc. (GILD). They have a “Buy” rating and a price target of $47.00 on the company.
Oppenheimer increased its EPS estimate on Infosys Technologies Ltd (INFY). They have a “market perform” rating on the company.
Barclays Capital raised its EPS estimate on News Corp. (NWSA). They have an “Equal Weight” rating and a price target of $20.00 on the company. They had had a “Buy” rating on the company before the change.
News Corp. (NWSA) closed Wednesday at $15.93, gaining $0.58, or 3.78 percent. Infosys Technologies closed at $61.26, falling $0.18, or 0.29 percent. Gilead Sciences closed at $41.61, rising $0.06, or 0.14 percent. Amgen closed at $56.61, dropping $0.29, or 0.51 percent. Apple closed at $358.02, jumping $4.27, or 1.21 percent.
Wednesday, May 18, 2011
Price Targets on (AMGN) (WINN) (DELL) (LLY) (TJX) Updated
Price targets on shares of Amgen, Inc. (NASDAQ: AMGN), Winn-Dixie Stores, Inc. (NASDAQ: WINN), Dell Inc. (NASDAQ: DELL), Eli Lilly & Co. (NYSE: LLY) and TJX Companies Inc (NYSE: TJX) updated by analysts.
Oppenheimer raised their price target on Amgen, Inc. (AMGN) to $66.00. They have an “outperform” rating on the company.
Barclays Capital (NYSE:BCS) raised their price target on Winn-Dixie Stores, Inc. (WINN) from $8.00 to $11.00. They have an “overweight” rating on the company.
Citigroup (NYSE:C) analysts raised their price target on shares of Dell Inc. (DELL) from $19.00 to $20.00. They now have a “buy” rating on the company.
Goldman Sachs analysts raised their price target on shares of Eli Lilly & Co. (NYSE: LLY) to $35.00. They now have a “sell” rating on the company.
Citigroup analysts cut their price target on shares of TJX Companies Inc (NYSE: TJX) to $46.00. They now have a “sell” rating on the company.
Oppenheimer raised their price target on Amgen, Inc. (AMGN) to $66.00. They have an “outperform” rating on the company.
Barclays Capital (NYSE:BCS) raised their price target on Winn-Dixie Stores, Inc. (WINN) from $8.00 to $11.00. They have an “overweight” rating on the company.
Citigroup (NYSE:C) analysts raised their price target on shares of Dell Inc. (DELL) from $19.00 to $20.00. They now have a “buy” rating on the company.
Goldman Sachs analysts raised their price target on shares of Eli Lilly & Co. (NYSE: LLY) to $35.00. They now have a “sell” rating on the company.
Citigroup analysts cut their price target on shares of TJX Companies Inc (NYSE: TJX) to $46.00. They now have a “sell” rating on the company.
Price Targets on (ADI) (AMGN) (ARUN) (COKE) (CSA) Updated
Price Targets on Analog Devices, Inc. (NYSE: ADI), Amgen, Inc. (NASDAQ: AMGN), Aruba Networks, Inc. (NASDAQ: ARUN), Coca-Cola Bottling Co. Consolidated (NASDAQ: COKE) and Cogdell Spencer Inc (NYSE: CSA) updated by analysts.
Deutsche Bank (NYSE:DB) raised their price target on Analog Devices, Inc. (ADI) to $42.00.
Bank of America (NYSE:BAC) raised their price target on Amgen, Inc. (AMGN) to $62.00.
Wedbush raised their price target on Aruba Networks, Inc. (ARUN) to $29.00.
Citigroup (NYSE:C) raised their price target on Coca-Cola Bottling Co. Consolidated (COKE) to $69.00.
Deutsche Bank raised their price target on Cogdell Spencer Inc (CSA) to $20.00.
Deutsche Bank (NYSE:DB) raised their price target on Analog Devices, Inc. (ADI) to $42.00.
Bank of America (NYSE:BAC) raised their price target on Amgen, Inc. (AMGN) to $62.00.
Wedbush raised their price target on Aruba Networks, Inc. (ARUN) to $29.00.
Citigroup (NYSE:C) raised their price target on Coca-Cola Bottling Co. Consolidated (COKE) to $69.00.
Deutsche Bank raised their price target on Cogdell Spencer Inc (CSA) to $20.00.
Friday, May 13, 2011
Price Targets on (ADES) (AMGN) (AU) (BCE) (CA) Updated
Price targets on ADA-ES Inc (NASDAQ: ADES), Amgen, Inc. (NASDAQ: AMGN), AngloGold Ashanti (NYSE: AU), BCE Inc. (NYSE: BCE) and CA Tech (NYSE: CA) were updated by analysts.
Wedbush cut their price target on ADA-ES Inc (ADES) from $21.00 to $13.00.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Amgen, Inc. (AMGN) from $65.00 to $70.00.
HSBC (NYSE:HBC) raised their price target on AngloGold Ashanti (AU) from $61.00 to $65.00. They have an “overweight” rating on the company.
RBC Capital raised their price target on BCE Inc. (BCE) from $37.00 to $40.00. They have an “outperform” rating on the company.
RBC Capital cut their price target on CA Tech (CA) from $30.00 to $28.00. They have an “outperform” rating on the company.
Wedbush cut their price target on ADA-ES Inc (ADES) from $21.00 to $13.00.
JPMorgan Chase & Co. (NYSE:JPM) raised their price target on Amgen, Inc. (AMGN) from $65.00 to $70.00.
HSBC (NYSE:HBC) raised their price target on AngloGold Ashanti (AU) from $61.00 to $65.00. They have an “overweight” rating on the company.
RBC Capital raised their price target on BCE Inc. (BCE) from $37.00 to $40.00. They have an “outperform” rating on the company.
RBC Capital cut their price target on CA Tech (CA) from $30.00 to $28.00. They have an “outperform” rating on the company.
Tuesday, May 10, 2011
Price Targets on (AMGN) (AVB) (CCIH) (CLP) (CPT) Updated
Price targets on Amgen, Inc. (NASDAQ: AMGN), AvalonBay Communities, Inc. (NYSE: AVB), Chinacache International Holdings Limited (NASDAQ: CCIH), Colonial Properties (NYSE: CLP) and Camden Property Trust (NYSE: CPT) updated by analysts.
MP Advisors raised their price target on Amgen, Inc. (AMGN) from $63.00 to $65.00. They have an “outperform” rating on the company.
FBR Capital raised their price target on AvalonBay Communities, Inc. (AVB) from $134.00 to $138.00. They have an “outperform” rating on the company.
Oppenheimer cut their price target on Chinacache International Holdings Limited (CCIH) from $28.00 to $26.00. They have an “outperform” rating on the company.
FBR Capital raised their price target on Colonial Properties (CLP) from $21.00 to $23.00. They have an “outperform” rating on the company.
FBR Capital raised their price target on Camden Property Trust (CPT) from $58.00 to $60.50. They have an “underperform” rating on the company.
MP Advisors raised their price target on Amgen, Inc. (AMGN) from $63.00 to $65.00. They have an “outperform” rating on the company.
FBR Capital raised their price target on AvalonBay Communities, Inc. (AVB) from $134.00 to $138.00. They have an “outperform” rating on the company.
Oppenheimer cut their price target on Chinacache International Holdings Limited (CCIH) from $28.00 to $26.00. They have an “outperform” rating on the company.
FBR Capital raised their price target on Colonial Properties (CLP) from $21.00 to $23.00. They have an “outperform” rating on the company.
FBR Capital raised their price target on Camden Property Trust (CPT) from $58.00 to $60.50. They have an “underperform” rating on the company.
Tuesday, April 5, 2011
Apple (AAPL) Crunched on Nasdaq 100 Rebalancing
News that the Nasdaq 100 will rebalance put the shares of Apple under pressure in pre-market trading, as its weighting in the index will be reduced, while others will get a boost.
According to Nasdaq, the rebalance is for the purpose of bringing weights back in line with the real market capitalizations of the companies listed.
For Apple, that means the company will be rebalanced from 20 percent to 12 percent of the index.
The rebalance will take effect on May 2, 2011, before the open of the market.
Some companies getting upwardly balance include Amgen (Nasdaq: AMGN) from 1.07 percent to 1.92 percent, Amazon.com (Nasdaq: AMZN) from 2.5 percent to 3.16 percent, Cisco (Nasdaq: CSCO) from 1.56 percent to 3.66 percent, Dell (Nasdaq: DELL) from 0.47 percent to 1.08 percent, Google (Nasdaq: GOOG) from 4.18 percent to 5.77 percent, Intel (Nasdaq: INTC) from 1.75 percent to 4.2 percent, Microsoft (Nasdaq: MSFT) from 3.41 percent to 8.32 percent, and Oracle (Nasdaq: ORCL) from 3.32 percent to 6.68 percent.
Apple was trading in pre-market at $336.59, down $4.60, or 1.35 percent.
According to Nasdaq, the rebalance is for the purpose of bringing weights back in line with the real market capitalizations of the companies listed.
For Apple, that means the company will be rebalanced from 20 percent to 12 percent of the index.
The rebalance will take effect on May 2, 2011, before the open of the market.
Some companies getting upwardly balance include Amgen (Nasdaq: AMGN) from 1.07 percent to 1.92 percent, Amazon.com (Nasdaq: AMZN) from 2.5 percent to 3.16 percent, Cisco (Nasdaq: CSCO) from 1.56 percent to 3.66 percent, Dell (Nasdaq: DELL) from 0.47 percent to 1.08 percent, Google (Nasdaq: GOOG) from 4.18 percent to 5.77 percent, Intel (Nasdaq: INTC) from 1.75 percent to 4.2 percent, Microsoft (Nasdaq: MSFT) from 3.41 percent to 8.32 percent, and Oracle (Nasdaq: ORCL) from 3.32 percent to 6.68 percent.
Apple was trading in pre-market at $336.59, down $4.60, or 1.35 percent.
Friday, April 1, 2011
JPMorgan (JPM) Down on (NAV) (PFG) (VLY)
Even though JPMorgan (NYSE:JPM) downgraded the consumer discretionary sector from "Overweight" to "Neutral," that didn't stop stocks like Ford (NYSE:F) from jumping, as they surpassed General Motors (NYSE:GM) in sales for the month of March. Gambling businesses like Las Vegas Sands (NYSE:LVS) also went against the grain, as they have been rising on news gambling revenue in Macau soared.
The reasoning JPMorgan had behind the downgrading of the consumer discretionary sector, which they view as a short-term event, was that it has been overall "structurally weaker" for some time. They also see economic momentum starting to slow down while the sector continues to have high valuations.
As for other sectors, they pointed out some of their favorites and least favorite stocks, with their worst ones including Valley National (NYSE:VLY), Navistar (NYSE:NAV) and Principal Financial Group (NYSE:PFG).
Stocks that found favor with JPMorgan, among a number of them, include Amgen (NASDAQ:AMGN), Gilead (NASDAQ:GILD), Aetna (NYSE:AET), Cigna (NYSE:CI), Delta Airlines (NYSE:DAL), UAL (NYSE:UAL), Medco Health Solutions (NYSE:MHS) and Life Technologies Corp (NASDAQ:LIFE).
The reasoning JPMorgan had behind the downgrading of the consumer discretionary sector, which they view as a short-term event, was that it has been overall "structurally weaker" for some time. They also see economic momentum starting to slow down while the sector continues to have high valuations.
As for other sectors, they pointed out some of their favorites and least favorite stocks, with their worst ones including Valley National (NYSE:VLY), Navistar (NYSE:NAV) and Principal Financial Group (NYSE:PFG).
Stocks that found favor with JPMorgan, among a number of them, include Amgen (NASDAQ:AMGN), Gilead (NASDAQ:GILD), Aetna (NYSE:AET), Cigna (NYSE:CI), Delta Airlines (NYSE:DAL), UAL (NYSE:UAL), Medco Health Solutions (NYSE:MHS) and Life Technologies Corp (NASDAQ:LIFE).
Monday, March 14, 2011
Amgen (AMGN), Anika (ANIK), Affymax (AFFY) Lead Biotech's Higher
Amgen (NASDAQ:AMGN), Anika Therapeutics (ANIK) and Affymax (AFFY) all closed up on Friday in an otherwise dismal day for biotech.
Anika Therapeutics (ANIK) continued to jump for the second day in a row as the impetus from their positive results in the fourth quarter continues to drive the shares. The company finished the week up by 21 percent.
Affymax Inc. (AFFY) was also hopping Friday after an upgrade from Auriga. It ended the week up by 15 percent.
Amgen (AMGN) closed out the week impressively as well, ended the day up over 3 percent. That move was attributed to the market believing the U.S. Food and Drug Administration labeling and Medicare reimbursement for a high-profile Amgen’s product will remain the same.
Amgen closed Friday at $53.53, up $1.69, or 3.26 percent. Anika closed at $11.17, gaining $1.54, or 15.99 percent. Affymax ended the session at $7.15, up $0.54, or 8.17 percent.
Anika Therapeutics (ANIK) continued to jump for the second day in a row as the impetus from their positive results in the fourth quarter continues to drive the shares. The company finished the week up by 21 percent.
Affymax Inc. (AFFY) was also hopping Friday after an upgrade from Auriga. It ended the week up by 15 percent.
Amgen (AMGN) closed out the week impressively as well, ended the day up over 3 percent. That move was attributed to the market believing the U.S. Food and Drug Administration labeling and Medicare reimbursement for a high-profile Amgen’s product will remain the same.
Amgen closed Friday at $53.53, up $1.69, or 3.26 percent. Anika closed at $11.17, gaining $1.54, or 15.99 percent. Affymax ended the session at $7.15, up $0.54, or 8.17 percent.
Monday, March 7, 2011
JPMorgan (JPM) Recommends Newmont (NEM), (FCX), (MUSA), (STLD), Others
JPMorgan (NYSE:JPM), says Newmont Mining Corp. (NYSE:NEM), Metals USA Holdings Corp. (NYSE:MUSA), Freeport-McMoRan Copper & Gold Inc. (NYSE:FCX) and Steel Dynamics Inc. (NASDAQ:STLD) are solid picks if an investor believes oil prices will remain high.
Also noted were Thompson Creek Metals Co. (NYSE:TC), DHT Holdings Inc. (NYSE:DHT), Amgen Inc. (NASDAQ:AMGN), Jabil Circuit Inc. (NYSE:JBL) and Gilead Sciences Inc. (NASDAQ:GILD) as having a lot of potential in a high oil price environment.
Thomas Lee, chief U.S. equity strategist at JPMorgan said there’s “downside risk” to the 2011 S&P 500 earnings-per-share estimate of $97.50, though not to the 1,425 year-end forecast.
Lee said every $20-a-barrel rise in the price of oil has an impact of $2.22 in earnings per share for the Standard & Poor’s 500 Index.
Stocks JPMorgan sees as those to avoid in this economic environment are Affymetrix Inc. (NASDAQ:AFFX), Standard Pacific Corp. (NYSE:SPF), MDC Holdings Inc. (NYSE:MDC) and Beazer Homes USA Inc. (NYSE:BZH).
Also noted were Thompson Creek Metals Co. (NYSE:TC), DHT Holdings Inc. (NYSE:DHT), Amgen Inc. (NASDAQ:AMGN), Jabil Circuit Inc. (NYSE:JBL) and Gilead Sciences Inc. (NASDAQ:GILD) as having a lot of potential in a high oil price environment.
Thomas Lee, chief U.S. equity strategist at JPMorgan said there’s “downside risk” to the 2011 S&P 500 earnings-per-share estimate of $97.50, though not to the 1,425 year-end forecast.
Lee said every $20-a-barrel rise in the price of oil has an impact of $2.22 in earnings per share for the Standard & Poor’s 500 Index.
Stocks JPMorgan sees as those to avoid in this economic environment are Affymetrix Inc. (NASDAQ:AFFX), Standard Pacific Corp. (NYSE:SPF), MDC Holdings Inc. (NYSE:MDC) and Beazer Homes USA Inc. (NYSE:BZH).
Tuesday, January 25, 2011
Amgen (NASDAQ:AMGN) Looks Good on Foundation Remaining Intact
Based on their solid base business, Barclays sees Amgen (NASDAQ:AMGN) continuing to perform strongly, with most of their segments looking lower risk.
Barclays says, "Overall, 4Q10 results were solid, guidance for 2011 is generally inline, and comments regarding denosumab franchise suggest increasing confidence in broadening Prolia Part D reimbursement, strong XGEVA launch, and robust '147 data on detailed review. With the acquisition of private oncolytic virus company BioVex, concerns regarding targeting patent challenged small molecule franchises should abate, although OncoVex should be considered high risk/high reward."
Barclays maintains an "Overweight" rating on Amgen (AMGN), which was trading at $57.02, down $0.27, or 0.47 percent, as of 2:39 PM EST. Barclays lowered their price target on Amgen from $76 to $72.
Barclays says, "Overall, 4Q10 results were solid, guidance for 2011 is generally inline, and comments regarding denosumab franchise suggest increasing confidence in broadening Prolia Part D reimbursement, strong XGEVA launch, and robust '147 data on detailed review. With the acquisition of private oncolytic virus company BioVex, concerns regarding targeting patent challenged small molecule franchises should abate, although OncoVex should be considered high risk/high reward."
Barclays maintains an "Overweight" rating on Amgen (AMGN), which was trading at $57.02, down $0.27, or 0.47 percent, as of 2:39 PM EST. Barclays lowered their price target on Amgen from $76 to $72.
Amgen (Nasdaq:AMGN) Income Up 10% on Neulasta, Neupogen and Lower Taxes
Net income for Amgen Inc. (Nasdaq:AMGN) jumped 10 percent in the fourth quarter, led by Neulasta and Neupogen, and a reduction in taxes.
Earnings for the quarter reached $1.02 billion, or $1.08 a share, up from $931 million, or 92 cents a share, in the same quarter last year.
Revenue rose to $3.84 billion, up from $3.81 billion last year, a one percent gain.
Aranesp and Epogen, the company's two anemia drugs, had sales drop considerably, falling to $1.22 billion, a 9 percent decline.
Amgen's 2011 guidance was lower than the Street was looking for, with earnings projected to come in at $5 to $5.20 a share for the year, on revenue of $15.1 billion to $15.5 billion.
The company could lose from $400 million to $500 million if Obamacare is kept in place. Up to $200 million of that would be in new federal excise fees.
Talking their acquisition of BioVex, Amgen said they expect to close the deal sometime in the first quarter.
Amgen closed Monday at $57.29, gaining $0.32, or 0.56 percent.
Earnings for the quarter reached $1.02 billion, or $1.08 a share, up from $931 million, or 92 cents a share, in the same quarter last year.
Revenue rose to $3.84 billion, up from $3.81 billion last year, a one percent gain.
Aranesp and Epogen, the company's two anemia drugs, had sales drop considerably, falling to $1.22 billion, a 9 percent decline.
Amgen's 2011 guidance was lower than the Street was looking for, with earnings projected to come in at $5 to $5.20 a share for the year, on revenue of $15.1 billion to $15.5 billion.
The company could lose from $400 million to $500 million if Obamacare is kept in place. Up to $200 million of that would be in new federal excise fees.
Talking their acquisition of BioVex, Amgen said they expect to close the deal sometime in the first quarter.
Amgen closed Monday at $57.29, gaining $0.32, or 0.56 percent.
Friday, January 21, 2011
Amgen (NASDAQ:AMGN) Targets Remain Intact on ESAs in CKD
After the CMS MEDCAC of ESAs in CKD review, Barclays found the results giving no reason for them to change their current targets on Amgen (NASDAQ:AMGN).
Barclays says, "We are maintaining our rating on AMGN following today's CMS MEDCAC review of ESAs in CKD. While the panel had low conviction regarding adequacy of data to support ESA use in preventing renal transplant rejection, expert commentary clearly established a logic pattern between transfusion avoidance, reduced antibody formation, and improved transplant outcomes. With the panel unable to vote on a lower end Hgb target of 10g/dl and with CMS suggesting sensitivity to panel commentary we see limited impetus to revise Hgb target ranges."
Barclays reiterates an "Overweight" rating on Amgen (AMGN), which closed at $57.31, gaining $0.33, or 0.58 percent. Barclays has a price target on Amgen of $76.
Barclays says, "We are maintaining our rating on AMGN following today's CMS MEDCAC review of ESAs in CKD. While the panel had low conviction regarding adequacy of data to support ESA use in preventing renal transplant rejection, expert commentary clearly established a logic pattern between transfusion avoidance, reduced antibody formation, and improved transplant outcomes. With the panel unable to vote on a lower end Hgb target of 10g/dl and with CMS suggesting sensitivity to panel commentary we see limited impetus to revise Hgb target ranges."
Barclays reiterates an "Overweight" rating on Amgen (AMGN), which closed at $57.31, gaining $0.33, or 0.58 percent. Barclays has a price target on Amgen of $76.
Subscribe to:
Posts (Atom)